What Are Peptides?

Peptides are short chains of amino acids — typically 2 to 50 amino acids linked together. They function as signaling molecules in the body, triggering specific biological processes when they bind to receptors on cell surfaces. Your body naturally produces thousands of peptides that regulate everything from growth and metabolism to immune function and tissue repair.

Peptide therapy involves administering synthetic versions of these natural signaling molecules — usually via subcutaneous injection — to amplify specific physiological processes. In the context of men's fitness and performance, the most popular peptides target healing and recovery, growth hormone release, and tissue repair.

The peptide space sits in a regulatory gray area. Most peptides used for performance purposes are not FDA-approved for those indications. They're typically obtained through compounding pharmacies, research chemical suppliers, or anti-aging clinics. The research base ranges from promising animal studies and compelling case reports to essentially no human clinical data — depending on the specific peptide.

BPC-157 (Body Protection Compound 157)

BPC-157 is arguably the most discussed peptide in fitness circles. It's a 15-amino acid peptide derived from a naturally occurring protein found in human gastric juice. Animal research on BPC-157 is extensive and remarkably positive.

What animal research shows:

  • Accelerated healing of tendons, ligaments, muscles, bone, and skin in rat models
  • Enhanced angiogenesis (formation of new blood vessels) at injury sites, improving blood supply for healing
  • Protective effects on the gastrointestinal tract — including healing of ulcers, inflammatory bowel disease models, and intestinal damage
  • Neuroprotective effects and potential for nerve healing
  • Anti-inflammatory properties without the immunosuppressive effects of corticosteroids

The human data gap: Despite overwhelmingly positive animal data, there are essentially no published human clinical trials for BPC-157 as of mid-2024. The human evidence consists entirely of anecdotal reports from athletes, lifters, and clinicians. Many of these reports are positive — describing accelerated healing of tendinitis, joint pain, muscle strains, and gut issues — but anecdotal evidence is inherently unreliable due to placebo effects, natural healing timelines, and reporting bias.

Typical protocols: 250 to 500 mcg per day via subcutaneous injection (near the injury site or in the abdominal area), run for 4 to 8 weeks. Some practitioners use oral BPC-157 for gut-related applications, though oral bioavailability is uncertain for systemic effects.

Reported side effects: BPC-157 appears to be well-tolerated in the available data, with minimal reported side effects. Injection site discomfort and occasional headaches are the most commonly noted issues.

TB-500 (Thymosin Beta-4)

TB-500 is a synthetic version of thymosin beta-4 (Tβ4), a naturally occurring peptide involved in cell migration, blood vessel formation, and tissue repair. It's widely used in performance and anti-aging contexts for its potential wound-healing and anti-inflammatory properties.

What research shows:

  • Promotes cell migration to injury sites, accelerating the initial phase of tissue repair
  • Stimulates angiogenesis and collagen deposition — critical processes in tendon, ligament, and muscle healing
  • Anti-inflammatory and anti-fibrotic (prevents excessive scar tissue formation) properties in animal models
  • Cardiac protective effects in post-heart attack animal models — improved cardiac function and reduced scar tissue

The human evidence: TB-500 has slightly more human context than BPC-157, as thymosin beta-4 has been studied in clinical trials for wound healing and dry eye syndrome. However, specific human trials for musculoskeletal healing in athletes or lifters are lacking.

Typical protocols: 2 to 5 mg administered via subcutaneous injection, 2 to 3 times per week during an initial loading phase (2 to 4 weeks), then reduced to once weekly for maintenance (4 to 6 additional weeks).

BPC-157 + TB-500 combination: Many practitioners and users combine BPC-157 and TB-500, theorizing that their complementary mechanisms (BPC-157 primarily enhances blood vessel formation and tissue repair signaling, while TB-500 promotes cell migration and reduces inflammation) produce synergistic healing effects. This combination is popular for treating chronic tendinitis, post-surgical recovery, and persistent joint issues. No clinical trials validate this combination protocol.

Growth Hormone Secretagogues

These peptides stimulate your pituitary gland to release more of its own growth hormone, rather than supplying exogenous GH directly:

Ipamorelin: A selective GH secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the "cleanest" GH-releasing peptides. Typical dose: 200 to 300 mcg, 2 to 3 times daily (usually before bed and/or upon waking). Expected to increase GH pulsatility modestly.

CJC-1295 (with DAC or without): A growth hormone releasing hormone (GHRH) analog that extends the natural GH pulse. Often combined with ipamorelin for enhanced effect. CJC-1295 with DAC (drug affinity complex) has a longer half-life and is dosed once or twice weekly. Without DAC, it requires more frequent dosing.

Tesamorelin: The only FDA-approved GH secretagogue — specifically for HIV-associated lipodystrophy. It's a GHRH analog that increases GH production and has been shown to reduce visceral abdominal fat. Some anti-aging clinicians prescribe it off-label.

Expected effects: GH secretagogues produce more modest effects than direct GH administration — typically 20 to 50% increases in GH output rather than the supraphysiological levels achieved with exogenous GH. Benefits may include improved sleep quality, modest improvements in body composition, enhanced recovery, and improved skin quality. Don't expect dramatic physique changes.

The Regulatory Landscape

In late 2023, the FDA placed several popular peptides (including BPC-157 and many GH secretagogues) on the Category 2 list under the Federal Food, Drug, and Cosmetic Act, effectively restricting compounding pharmacies from producing them. This has created significant supply disruption and pushed some users toward less regulated sources.

This regulatory action highlights two realities: (1) these peptides were never FDA-approved for the conditions they were being used for, and (2) the safety and efficacy data available do not meet the standards required for pharmaceutical approval. Men considering peptide therapy should understand they are operating in a relatively unregulated space with limited human safety data.

Risk Considerations

  • Quality and purity: Non-pharmaceutical peptides vary dramatically in quality. Products from unregulated suppliers may contain contaminants, incorrect dosing, or entirely different compounds than advertised. If pursuing peptide therapy, source from reputable compounding pharmacies with third-party testing.
  • Unknown long-term effects: Most peptides lack long-term human safety data. The absence of known side effects is not the same as evidence of safety. Particularly for peptides that stimulate cell growth and angiogenesis, theoretical concerns about cancer risk exist — though no evidence currently supports this concern for therapeutic doses.
  • Drug interactions: Peptide interactions with other medications are poorly studied. Inform your physician about any peptides you're using.
  • Legal considerations: The legal status of many peptides is evolving. What was available through compounding pharmacies in 2023 may be restricted by 2025. Stay informed about current regulations.

Key Takeaways

  • BPC-157 and TB-500 have promising animal data for tissue healing, but virtually no published human clinical trials. Anecdotal reports from athletes are positive but unreliable as evidence.
  • GH secretagogues (ipamorelin, CJC-1295) produce modest increases in natural GH output and may support recovery, sleep, and body composition — but effects are far less dramatic than exogenous GH.
  • The regulatory landscape is evolving. The FDA has restricted compounding of several popular peptides, limiting access through traditional medical channels.
  • Quality and purity vary widely between sources. Use only reputable compounding pharmacies with third-party testing if pursuing peptide therapy.
  • Peptide therapy should be viewed as experimental. The evidence base is promising but incomplete, and men should approach it with appropriate caution and medical oversight.